MedTrace Logo

Study of AK119 Combined With AK104 in Patients With Advanced Solid Tumors

NCT05559541 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2025-02-19

No results posted yet for this study

Summary

This is a Phase Ib/II Study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of AK119 combined with AK104 in tumor patients.

Conditions

  • Solid Tumor, Adult

Interventions

DRUG

AK119

AK119 is an anti-CD73 monoclonal antibody.

DRUG

AK104

AK104 is an anti-PD-1 and CTLA-4 bispecific antibody.

Sponsors & Collaborators

Principal Investigators

  • Jihui Hao, PhD · Tianjin Medical University Cancer Insitute & Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-12-15
Primary Completion
2024-05-31
Completion
2024-05-31

Countries

  • China

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05559541 on ClinicalTrials.gov